| P50 | author | Miguel A. Piris | Q37831476 |
| | Carmen Blanco-Aparicio | Q48975692 |
| | José Luis Rodríguez-Peralto | Q61937654 |
| | Margarita Sanchez-Beato | Q71512307 |
| | Esperanza Martin-Sanchez | Q84043346 |
| P2093 | author name string | Manuela Mollejo | |
| | Juan F García | |
| | Magdalena B Wozniak | |
| | James R Bischoff | |
| | Diana Romero | |
| | Pablo García-Sanz | |
| | Pablo L Ortiz-Romero | |
| | Socorro M Rodríguez-Pinilla | |
| | Javier Menárguez | |
| | Guido Kurz | |
| | Luis Lombardía | |
| | Lina Odqvist | |
| | Fernando González-Palacios | |
| | Beatriz Domínguez-González | |
| | F Javier Alves | |
| P2860 | cites work | Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles | Q24536351 |
| | The PI3K pathway as drug target in human cancer | Q24632283 |
| | Impaired B and T cell antigen receptor signaling in p110delta PI 3-kinase mutant mice | Q28215433 |
| | PI3Kδ inhibitor, GS-1101 (CAL-101), attenuates pathway signaling, induces apoptosis, and overcomes signals from the microenvironment in cellular models of Hodgkin lymphoma | Q28256448 |
| | Phosphoinositide 3-kinase activity in T cells regulates the magnitude of the germinal center reaction | Q28292732 |
| | Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 |
| | The Connectivity Map: using gene-expression signatures to connect small molecules, genes, and disease | Q29547614 |
| | Targeting PI3K signalling in cancer: opportunities, challenges and limitations | Q29617685 |
| | Vorinostat: a new oral histone deacetylase inhibitor approved for cutaneous T-cell lymphoma | Q33375694 |
| | Activity of any class IA PI3K isoform can sustain cell proliferation and survival. | Q33952917 |
| | Phosphatidylinositol 3-kinase-δ inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals | Q34184717 |
| | New strategies in peripheral T-cell lymphoma: understanding tumor biology and developing novel therapies | Q34683488 |
| | The PTEN-PI3K pathway: of feedbacks and cross-talks | Q34828662 |
| | The role of phosphatidylinositol 3-kinase-δ in the immunomodulatory effects of lenalidomide in chronic lymphocytic leukemia | Q34923824 |
| | Drugging the PI3 kinome: from chemical tools to drugs in the clinic. | Q35622141 |
| | PI3K signalling in B- and T-lymphocytes: new developments and therapeutic advances | Q36516932 |
| | High frequency of PTEN, PI3K, and AKT abnormalities in T-cell acute lymphoblastic leukemia | Q37268926 |
| | Molecular classification of T-cell lymphomas | Q37398316 |
| | Chemical interrogation of FOXO3a nuclear translocation identifies potent and selective inhibitors of phosphoinositide 3-kinases | Q37460004 |
| | High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade. | Q37635287 |
| | NOTCH and phosphatidylinositide 3-kinase/phosphatase and tensin homolog deleted on chromosome ten/AKT/mammalian target of rapamycin (mTOR) signaling in T-cell development and T-cell acute lymphoblastic leukemia | Q37861191 |
| | Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 |
| | Present and future of PI3K pathway inhibition in cancer: perspectives and limitations | Q37886008 |
| | The PI3K/PKB signaling module as key regulator of hematopoiesis: implications for therapeutic strategies in leukemia. | Q37953891 |
| | PI3Kδ inhibitors in cancer: rationale and serendipity merge in the clinic | Q38010180 |
| | Vorinostat for treatment of cutaneous manifestations of advanced primary cutaneous T-cell lymphoma | Q39336768 |
| | CAL-101, a p110delta selective phosphatidylinositol-3-kinase inhibitor for the treatment of B-cell malignancies, inhibits PI3K signaling and cellular viability | Q39642145 |
| | In vivo antitumor activity of MEK and phosphatidylinositol 3-kinase inhibitors in basal-like breast cancer models. | Q39830937 |
| | PI3K p110delta regulates T-cell cytokine production during primary and secondary immune responses in mice and humans | Q41367429 |
| | Correlating phosphatidylinositol 3-kinase inhibitor efficacy with signaling pathway status: in silico and biological evaluations | Q43041602 |
| | Phosphoinositide 3'-kinase delta: turning off BCR signaling in Chronic Lymphocytic Leukemia.. | Q43041958 |
| | Physiological PTEN expression in peripheral T-cell lymphoma not otherwise specified. | Q43103123 |
| | Phosphorylated AKT protein is overexpressed in human peripheral T-cell lymphomas and predicts decreased patient survival | Q83380075 |
| | Peripheral T-cell lymphoma | Q83865733 |
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 57-64 | |
| P577 | publication date | 2012-07-16 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Simultaneous inhibition of pan-phosphatidylinositol-3-kinases and MEK as a potential therapeutic strategy in peripheral T-cell lymphomas | |
| P478 | volume | 98 | |